Emily joined the Hata Lab in June 2022 after receiving her BA from College of the Holy Cross. At Holy Cross, Emily was a Biology/Chinese double major, and worked in Dr. Alexis Hill’s Drosophila Neurobiology lab. Her work focused on the gene seizure (sei) and how it affects developmental time in Drosophila, along with determining which cell types express sei. In the Hata lab, she is a member of the Model Development Team which seeks to create cell lines and PDX models from patient lung cancer samples. Outside of lab, Emily enjoys doing ballet, playing with her cat, and spending time with friends and family.
The CCR Retreat is back! Hata Lab research was well represented by posters from Samar, Jamie, Hideko, Chendi and Justine.
Aya, Jess and Satoshi’s manuscript
“Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer” is now published in Nature Cancer! This collaboration with the Pfizer lorlatinib team presents specific strategies for targeting different classes of ALK compound resistance mutations.
Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BW, Gainor JF, Lin JJ, Yoda S, Hata AN. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature Cancer. 2022 Jun 20. doi: 10.1038/s43018-022-00399-6. Online ahead of print.PMID: 35726063
Welcome to Emily Hensley who joins our group as a research technician on the model development team.
